Shots:
- BioMarin has entered into a definitive agreement to acquire Amicus, strengthening BioMarin’s commercial portfolio with Galafold (migalastat) for Fabry Disease & Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) for Pompe Disease
- As per the deal, BioMarin will acquire Amicus for $14.5/share in an all-cash transaction for a total equity value of ~$4.8B; closing is expected in Q2’26
- Amicus also holds US rights to DMX-200, a small-molecule therapy for focal segmental glomerulosclerosis, currently in P-III trial development
Ref: BioMarin| Image: Amicus|Press Release
Related News: Sobi to Acquire Arthrosi Therapeutics for ~$1.5B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
